

Sekkei Bio implements CDD Vault to centralize research data

Sekkei Bio, an India-based company dedicated to drug and vaccine design, has implemented CDD Vault as the main platform to house its research data.


BENGALORE, INDIA, September 15, 2022 /EINPresswire.com/ --

Collaborative Drug Discovery (CDD) announced today that Sekkei Bio, an India-based company dedicated to building cutting-edge technologies for drug and vaccine design with global impact, has implemented [CDD Vault](#) as the main platform to house its research data. Sekkei has made big progress toward finding therapies for diabetes and pain.

Sekkei Bio has a management team with a long track record of successfully bringing drugs to market. The company has built an in-silico discovery engine based on this experience, which allows them to design and develop novel drugs and excipients. The in-silico engine drives their in-house programs and can also be accessed by other organizations through a range of flexible collaboration options. Sekkei Bio has also created an mRNA platform that provides a cost-effective and scalable solution for vaccines and therapeutics adapted to the regional need.

Key to the progress of the Sekkei drug discovery program is the implementation of CDD Vault to store, manage and analyze their research data - including peptides, small molecules, and assay data - used to model the new drugs. The implementation of CDD Vault is key to the company's collaborations as it enables data security right from query handling to library handover and allows for interactions with partners and collaborators in real time.

"Several of us at Sekkei have worked with CDD in previous tenures. We knew of the power of the



platform and how it will help organize data and make them traceable, searchable and reusable," said Dr. Monalisa Chatterji, Director and co-founder at Sekkei Bio. "Clean and organized data are the cornerstone of IP-able scientific progress. It is important to us to keep the traceability of the data and ensure that our data is secure yet readily accessible at the same time," stated Dr. Anirudh Ranganathan, co-founder of Sekkei Bio.

"We have known the Sekkei team for a long time, and they have an impressive track record delivering new drugs. We are proud that CDD Vault will be supporting their research again in this new venture," said Dr Barry Bunin, CEO of CDD.

ABOUT COLLABORATIVE DRUG DISCOVERY, INC.

CDD's (www.collaborativedrug.com) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

Abraham Wang
Collaborative Drug Discovery

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)



This press release can be viewed online at: <https://www.einpresswire.com/article/590755350>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.